Moderna, Inc. (MRNA) Guidance & Earnings Results
On 2026-07-31 Moderna, Inc. reaffirmed guidance: "Targeting up to 10% revenue growth; R&D expenses lowered to ~$2.9B; year-end cash…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MRNAModerna, Inc.Follow MRNA — free
—
Price chart with a free account
- Market cap
- 79.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Nov, in 13 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 31 Jul 26 | Reaffirmed | Targeting up to 10% revenue growth; R&D expenses lowered to ~$2.9B; year-end cash $4.7-$5.2B · full year |
| 1 May 26 | Reaffirmed | Up to 10% revenue growth; R&D ~$3.0B; SG&A ~$1.0B; capex $0.2-0.3B · full year |
| 13 Feb 26 | Reaffirmed | Up to 10% revenue growth in 2026 |
| 12 Jan 26 | Raised | 2025 revenue ~$1.9B vs prior midpoint of $1.8B; 2026 revenue growth up to 10% |
| 6 Nov 25 | Lowered | Revenue range narrowed to $1.6-2.0B from $1.5-2.2B · full year |
| 1 Aug 25 | Lowered | FY2025 revenue $1.5-2.2B (from $1.5-2.5B, high end cut $300M); R&D $3.6-3.8B (from ~$4.1B); capex ~$0.3B (from ~$0.4B); COGS ~$1.2B; SG&A ~$1.1B; year-end cash ~$6B · full year |
Moderna, Inc. — questions
- What guidance did Moderna, Inc. give?
- On 2026-07-31: "Targeting up to 10% revenue growth; R&D expenses lowered to ~$2.9B; year-end cash $4.7-$5.2B"
- When does Moderna, Inc. report earnings?
- Moderna, Inc.'s next earnings report is expected on 2026-11-06.
Every figure on this page comes from Moderna, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.